Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;26(7):1676-1682.
doi: 10.1177/1078155220953198. Epub 2020 Aug 27.

Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

Semih Başcı  1 , Naim Ata  2 , Fevzi Altuntaş  1 , Tuğçe Nur Yiğenoğlu  1 , Mehmet Sinan Dal  1 , Serdal Korkmaz  3 , Sinem Namdaroğlu  4 , Abdülkadir Baştürk  5 , Tuba Hacıbekiroğlu  6 , Mehmet Hilmi Doğu  7 , İlhami Berber  8 , Kürşat Dal  9 , Mehmet Ali Erkurt  8 , Burhan Turgut  10 , Murat Çağlayan  11 , Mustafa Okan Ayvalı  12 , Osman Çelik  13 , Mustafa Mahir Ülgü  12 , Şuayip Birinci  14 ; Turkish Ministry of Health, Hematology Scientific Working Group
Affiliations

Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

Semih Başcı et al. J Oncol Pharm Pract. 2020 Oct.

Abstract

Introduction: In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI).

Method: The data of 16 laboratory-confirmed COVID-19 patients with CML receiving TKI and age, gender, and comorbid disease matched COVID-19 patients without cancer at a 3/1 ratio (n = 48), diagnosed between March 11, 2020 and May 22, 2020 and included in the Republic of Turkey, Ministry of Health database, were analyzed retrospectively.

Results: The rates of intensive care unit (ICU) admission, and mechanical ventilation (MV) support were lower in CML patients compared to the control group, however, these differences did not achieve statistical significance (p = 0.1, and p = 0.2, respectively). The length of hospital stay was shorter in CML patients compared with the control group; however, it was not statistically significant (p = 0.8). The case fatality rate (CFR) in COVID-19 patients with CML was 6.3%, and it was 12.8% in the control group. Although the CFR in CML patients with COVID-19 was lower compared to the control group, this difference did not achieve statistical significance (p = 0.5). When CML patients were divided into 3 groups according to the TKI, no significant difference was observed regarding the rate of ICU admission, MV support, CFR, the length of stay in both hospital and ICU (all p > 0.05).

Conclusion: This study highlights that large scale prospective and randomized studies should be conducted in order to investigate the role of TKIs in the treatment of COVID-19.

Keywords: COVID-19; SARS-CoV-2; Tyrosine kinase inhibitors; chronic myeloid leukemia.

PubMed Disclaimer

Comment in

References

    1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382: 1199–1207. - PMC - PubMed
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733. - PMC - PubMed
    1. Shoenfeld Y.Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev 2020; 19: 102538. - PMC - PubMed
    1. Kanduc D, Shoenfeld Y.On the molecular determinants and the mechanism of the SARS-CoV-2 attack 2020. Clin Immunol 2020; 215: 108426. - PMC - PubMed
    1. World Health Organization Press Conference. The World Health Organization (WHO) has officially named the disease caused by the novel coronavirus as COVID-19, https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed 18 May 2020).

MeSH terms